FDA Approval Activities for this Drug
Emtriva (emtricitabine) Capsules, 200 mg Gilead Sciences, NDA 21-500 Truvada, (emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg)) tablets, Gilead Sciences, Approval | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | Emtriva (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | EMTRIVA (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | TRUVADA Tablets, Gilead Sciences, Accelerated Approval | EMTRIVA (emtricitabine) Oral Solution, Gilead Sciences, Patient Population Altered & Labeling Revision | Truvada (emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision
| Emtriva (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | Emtriva (emtricitabine) Oral Solution, Gilead Sciences, Labeling Revision | Emtricitabine Capsules, Aurobindo Pharma USA, Inc., Tentative Approval | Emtriva (emtricitabine) Capsules, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Emtriva (emtricitabine) Oral Solution, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision